Nilandron Drug Interactions: 40 Major, 394 Moderate
Nilandron (Nilutamide) Drug Interactions
Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Nilandron. Always confirm against the full prescribing information.
100 interactions
Abacavir
Nilutamide may increase the hepatotoxic activities of Abacavir.
Level 2 evidence
Abatacept
The metabolism of Nilutamide can be increased when combined with Abatacept.
Level 1 evidence
Abiraterone
Nilutamide may increase the hepatotoxic activities of Abiraterone.
Level 2 evidence
Abrocitinib
The metabolism of Abrocitinib can be decreased when combined with Nilutamide.
Level 2 evidence
Acarbose
Acarbose may increase the hepatotoxic activities of Nilutamide.
Level 2 evidence
Acetaminophen
Acetaminophen may increase the hepatotoxic activities of Nilutamide.
Level 2 evidence
Acetazolamide
Nilutamide may increase the hepatotoxic activities of Acetazolamide.
Level 2 evidence
Acetylsalicylic acid
The metabolism of Acetylsalicylic acid can be decreased when combined with Nilutamide.
Level 2 evidence
Acitretin
Acitretin may increase the hepatotoxic activities of Nilutamide.
Level 2 evidence
Adalimumab
The metabolism of Nilutamide can be increased when combined with Adalimumab.
Level 1 evidence
Aficamten
The metabolism of Aficamten can be decreased when combined with Nilutamide.
Level 2 evidence
Albendazole
The metabolism of Albendazole can be decreased when combined with Nilutamide.
Level 2 evidence
Enter your NPI to unlock 3 major interactions for Nilandron
Nilandron (Nilutamide) has 936 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Nilandron (Nilutamide) has 40 major, 394 moderate, and 502 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Nilandron. Always confirm against the full prescribing information.